Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Presentation prepared and held by Dr Kees Hovingh (AMC Amsterdam) in Clinical Breakthroughs session: Modifying LDL cholesterol to prevent CV events, Tuesday, May 26, 2015 during ISA2015 (Amsterdam, The Netherlands).
To view slides, click on images
Alirocumab Treatment Effect Did Not Differ Between Patients.pdf (0,7MB)
To view slides, click on images
Alirocumab Treatment Effect Did Not Differ Between Patients.pdf (0,7MB)
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
Share this page with your colleagues and friends: